Rigel Pharmaceuticals is dedicated to discovering, developing and providing novel small molecule drugs for immune and hematologic disorders, cancer and rare diseases. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. TAVALISSE was approved on April 17th 2018 and became available by prescription in the US on May 29th 2018. Other programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy.
1180 Veterans Blvd
San Francisco, CA 94080
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by